Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25329927 | 0.88 | TP53 (0.32) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL25330179 | 0.86 | TP53 (0.31) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL25328994 | 0.85 | ALOX15 (0.33) | ALOX15ESR1ESR2 | |
| SCHEMBL25328225 | 0.80 | CYP3A4 (0.42) | ESR1ESR2CYP3A4ACHE | |
| SCHEMBL25329808 | 0.80 | ACHE (0.36) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL25329103 | 0.79 | ALDH1A1 (0.42) | CYP2D6CYP2C9ALOX15CYP2C19ESR1 | |
| SCHEMBL25329419 | 0.76 | PTGS1 (0.36) | ESR1CYP3A4ACHE | |
| SCHEMBL25328780 | 0.76 | SCN5A (0.32) | ALOX15CYP3A4ACHE | |
| SCHEMBL25329799 | 0.74 | TP53 (0.30) | TP53CYP2C9CYP2C19 | |
| SCHEMBL25327947 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-4161892-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-04-12 | — | — | EP | disclosed |
| CN-115697954-A | Polymerization inhibitor | 巴斯夫欧洲公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | TP53 2223/4885CYP2D6 3350/4885CYP2C9 4119/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | TP53 4081/4885CYP2D6 1322/4885CYP2C9 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.